5x broker valuation of 33c, page-15

Great stuff @ViperX1 .  Let me check that I understand completely:

- After 91 patients the 12 week separation between VF-001 treated patients and the control arm (assuming control and placebo are identical) is 22% (45% wound closure for VenUS-III less 23% for implied aggregate active).
- Thus if the control arm and placebo are identical this is comfortably above the 10% threshold and the trial will be a raging success.
- However we we assume the placebo arm outperforms the control arm, then we have room for it to outperform by 17.5% on a relative scale or around 8% on an absolute scale and we will still sneak in with the required 10% wound closure difference.